Literature DB >> 3860466

Chronic myelomonocytic leukemia: clinical features, cytogenetics, and prognosis in 30 consecutive cases.

E P Alessandrino, E Orlandi, E Brusamolino, M Lazzarino, E Morra, C Castagnola, C Bernasconi.   

Abstract

A retrospective analysis of 30 patients with chronic myelomonocytic leukemia (CrMML) was performed to define the natural history of the disease and the risk of acute transformation. Our patients fulfilled the following criteria of diagnosis: blood monocytosis over 1 X 10(9)/l, blast cell percentage in bone marrow up to 30, and in peripheral blood less than 5. The most common presenting feature was anemia; seven patients had fever; three patients complained of purpura and bleeding. Anysopoikilocytosis and macrocytosis were frequent. Abnormal granulocyte morphology, defective granulation and abnormal leukocyte alkaline phosphatase were often observed. Blast cells in peripheral blood smears were found in 14 patients. Serum and urine lysozyme levels were increased in 82 per cent and 93 per cent, respectively. Dysplastic changes involving erythroid, granulocytic and megakaryocytic lineages were constant features in all cases. Agranulated blasts above 5 per cent of marrow nucleated cells were seen in 13 patients (43 per cent). Seven of the 20 patients showed non-specific chromosomal abnormalities at diagnosis. Median survival from diagnosis was 18 months (range, 3-112). Evolution into acute myeloid leukemia occurred in 11 patients. No difference in survival was found between patients who developed acute leukemia and patients who did not. A shorter survival has correlated to the following parameters: leukocytes greater than 10 X 10(9)/l, the presence of blasts in peripheral blood and agranulated blasts in the marrow above 5 per cent.

Entities:  

Mesh:

Year:  1985        PMID: 3860466     DOI: 10.1002/hon.2900030206

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  7 in total

1.  Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome.

Authors:  E Montefusco; G Alimena; F Lo Coco; M R De Cuia; Y Z Wang; M A Aloe Spiriti; F Mancini; M Cedrone; M Mancini; F Mandelli
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Obstructive uropathy associated with myelomonocytic infiltration of the prostate.

Authors:  B Hope-Gill; J R Goepel; R C Collin
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

3.  Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia.

Authors:  C R Bradford; S R Smith; J P Wallis
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

Review 4.  Models of Prognostication in Chronic Myelomonocytic Leukemia.

Authors:  Francesco Onida
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 5.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

6.  Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).

Authors:  A N Stark; J Thorogood; C Head; B E Roberts; C S Scott
Journal:  Br J Cancer       Date:  1987-07       Impact factor: 7.640

7.  Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.

Authors:  Antònia Banús-Mulet; Amaia Etxabe; Josep Maria Cornet-Masana; Miguel Ángel Torrente; María Carmen Lara-Castillo; Laura Palomo; Meritxell Nomdedeu; Marina Díaz-Beyá; Francesc Solé; Benet Nomdedeu; Jordi Esteve; Ruth M Risueño
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.